secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lexaria Bioscience Corp. (LEXX)
CIK:        0001348362
Form:       8-K
Filed at:   2025-02-05T23:59:59+00:00
Accession:  0001640334-25-000192
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lexaria reduces at-the-market equity facility from $20M to $5M
--------------------------------------------------------------

- Amended Capital on Demand Sales Agreement with JonesTrading; maximum aggregate principal amount reduced to $5M from $20M.
- Shares sold under new registration statement on Form S-3 (333-284407), effective Jan 30, 2025.
- Agent commission remains 3.0% of gross sales price; customary indemnification and expense reimbursement.
- Offering terminates upon sale of all Shares or termination of agreement by either party.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1348362/000164033425000192/0001640334-25-000192-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1348362/000164033425000192/lxrp_8k.htm
  HTML page:      https://secwatch.observer/filing/0001640334-25-000192

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer